Helicos shares began trading on the Nasdaq exchange last week, but not before the company cut by 40 percent its original per-share offering price.
 
Helicos, which became the only publicly traded pure-play next-generation sequencing shop, floated its 5.4 million shares at $9 apiece to raise around $43.2 million in net proceeds.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.